Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 177.38M | 196.87M | 179.52M | 181.10M | 168.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 177.38M | 196.87M | 179.52M | 181.10M | 168.92M |
| Cost of Revenue | 36.41M | 45.80M | 34.28M | 40.87M | 34.31M |
| Gross Profit | 140.96M | 151.07M | 145.24M | 140.23M | 134.62M |
| SG&A Expenses | 93.94M | 101.61M | 91.80M | 88.58M | 86.78M |
| Depreciation & Amortization | 14.32M | 14.32M | 14.32M | 14.32M | 14.32M |
| Other Operating Expenses | -- | -- | -- | -- | 351.00K |
| Total Operating Expenses | 172.75M | 199.18M | 166.36M | 171.97M | 161.10M |
| Operating Income | 4.63M | -2.31M | 13.15M | 9.13M | 7.83M |
| Income Before Tax | 5.00M | 571.00K | 9.52M | -1.93M | 8.71M |
| Income Tax Expenses | 2.08M | -1.07M | 4.09M | 2.92M | 3.89M |
| Earnings from Continuing Operations | 2.92M | 1.64M | 5.43M | -4.85M | 4.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.92M | 1.64M | 5.43M | -4.85M | 4.81M |
| EBIT | 4.63M | -2.31M | 13.15M | 9.13M | 7.83M |
| EBITDA | 25.96M | 24.53M | 28.84M | 36.46M | 28.99M |
| EPS Basic | 0.07 | 0.04 | 0.12 | -0.11 | 0.10 |
| Normalized Basic EPS | 0.04 | -0.06 | 0.25 | -0.02 | 0.14 |
| EPS Diluted | 0.07 | 0.04 | 0.12 | -0.11 | 0.10 |
| Normalized Diluted EPS | 0.04 | -0.06 | 0.24 | -0.02 | 0.14 |
| Average Basic Shares Outstanding | 40.46M | 42.49M | 44.04M | 45.46M | 46.28M |
| Average Diluted Shares Outstanding | 40.91M | 42.98M | 44.46M | 45.46M | 46.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |